Merck also known as MSD outside the U.S. and Canada, announced that it will present new research data on HIV prevention and treatment at the 13th International AIDS Society Conference on HIV Science (IAS 2025), scheduled for July 13-17, 2025, in Kigali, Rwanda.
The business will showcase scientific advancements from its HIV clinical development initiatives, such as Phase 2 data assessing the pharmacokinetics and safety of MK-8527, an experimental nucleoside reverse transcriptase translocation inhibitor being developed as an oral once-monthly HIV pre-exposure prophylactic (PrEP) treatment.
